688235 百济神州
已收盘 03-28 15:00:00
资讯
新帖
简况
百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%
界面 · 03-28 20:07
百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%
百济神州:2023年净亏损8.89亿元
财通社 · 03-28 19:03
百济神州:2023年净亏损8.89亿元
百济神州发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位
智通财经 · 03-28 18:40
百济神州发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位
百济神州诉外企侵犯专利 国内药企要学新的一课
经济观察网 · 03-27 17:20
百济神州诉外企侵犯专利 国内药企要学新的一课
百济神州-U03月27日遭主力抛售447万元 环比增加964.29%
自选股智能写手 · 03-27 15:20
百济神州-U03月27日遭主力抛售447万元 环比增加964.29%
百济神州3月26日获南向资金加仓54.59万股
自选股智能写手 · 03-27 09:31
百济神州3月26日获南向资金加仓54.59万股
百济神州(苏州)生物科技有限公司申请III类会议
金融界 · 03-26 06:41
百济神州(苏州)生物科技有限公司申请III类会议
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
太平洋证券股份... · 03-26
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
百济神州-U03月25日主力资金流出1502万元 连续3日减仓
自选股智能写手 · 03-25
百济神州-U03月25日主力资金流出1502万元 连续3日减仓
创新药融资承压,百济神州还能跨过盈亏平衡线吗?
松果财经 · 03-25
创新药融资承压,百济神州还能跨过盈亏平衡线吗?
百济神州盘中异动 早盘急速跳水5.27%
自选股智能写手 · 03-22
百济神州盘中异动 早盘急速跳水5.27%
百济神州(06160)股价下跌8.095%,现价港币$93.1
阿斯达克财经 · 03-22
百济神州(06160)股价下跌8.095%,现价港币$93.1
百济神州获融资买入0.13亿元,近三日累计买入0.28亿元
金融界 · 03-22
百济神州获融资买入0.13亿元,近三日累计买入0.28亿元
百济神州:公司独立非执行董事Olivier Brandicourt博士获委任为董事会商业及医学事务咨询委员会成员
每日经济新闻 · 03-21
百济神州:公司独立非执行董事Olivier Brandicourt博士获委任为董事会商业及医学事务咨询委员会成员
百济神州获北向资金卖出2214.5万元,累计持股475.9万股
金融界 · 03-20
百济神州获北向资金卖出2214.5万元,累计持股475.9万股
人工智能+”行动出台,哪些板块有望受益?
银华基金 · 03-20
人工智能+”行动出台,哪些板块有望受益?
百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万
阿斯达克财经 · 03-18
百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万
美银证券升百济神州目标价至108.27港元 评级中性
财通社 · 03-18
美银证券升百济神州目标价至108.27港元 评级中性
大行评级|里昂:上调百济神州目标价至138.5港元 重申“买入”评级
格隆汇资讯 · 03-18
大行评级|里昂:上调百济神州目标价至138.5港元 重申“买入”评级
百济神州3月15日获南向资金加仓79.97万股
自选股智能写手 · 03-18
百济神州3月15日获南向资金加仓79.97万股
加载更多
公司概况
公司名称:
百济神州有限公司
所属行业:
医药制造业
上市日期:
2021-12-15
主营业务:
百济神州有限公司是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物,主要产品百悦泽((BRUKINSA),BTK抑制剂)、百泽安(抗PD-1单抗)、帕米帕利。公司自主研发产品BRUKINSA(百悦泽)实现了中国原研新药出海的“零突破”,并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年,公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外,公司作为承担单位进行了5项国家级科研项目,并在核心期刊上发表了34篇学术论文。
发行价格:
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":130.77,"timestamp":1711609200000,"preClose":130.24,"halted":0,"volume":1103942,"delay":0,"floatShares":114999999,"shares":1358000000,"eps":-5.2201,"marketStatus":"已收盘","marketStatusCode":5,"change":0.53,"latestTime":"03-28 15:00:00","open":130.18,"high":132.79,"low":129.8,"amount":145000000,"amplitude":0.023,"askPrice":130.79,"askSize":2,"bidPrice":130.77,"bidSize":22,"shortable":0,"etf":0,"ttmEps":-5.2201,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1711675800000},"adr":0,"adjPreClose":130.24,"symbolType":"stock_kcb","openAndCloseTimeList":[[1711589400000,1711596600000],[1711602000000,1711609200000]],"highLimit":143.26,"lowLimit":117.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1357560499,"pbRate":6.5,"roa":"--","roe":"--","epsLYR":-10.18,"committee":0.361111,"marketValue":177528000000,"floatMarketCap":15046000000,"peRate":-25.051245,"changeRate":0.0041,"turnoverRate":0.0096,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-04-02。","afterMarket":{"amount":0,"volume":0,"close":130.77,"buyVolume":0,"sellVolume":0,"time":1711611238379,"indexStatus":"已收盘 03-28 15:30:00","preClose":130.24}},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2422316772","title":"百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422316772","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2422316772?lang=zh_cn&edition=full","pubTime":"2024-03-28 20:07","pubTimestamp":1711627627,"startTime":"0","endTime":"0","summary":"百济神州3月28日公告,截至2023年12月31日止年度的收入合计较截至2022年12月31日止年度增加约10亿美元或约73.7%至约25亿美元。截至2023年12月31日止年度的净亏损较截至2022年12月31日止年度减少约11亿美元或约56.0%至约8.82亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328200707791d94f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328200707791d94f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422116935","title":"百济神州:2023年净亏损8.89亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422116935","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2422116935?lang=zh_cn&edition=full","pubTime":"2024-03-28 19:03","pubTimestamp":1711623780,"startTime":"0","endTime":"0","summary":"百济神州公告,截至2023年12月31日止年度的净亏损较截至2022年12月31日止年度减少约11亿美元或约56.0%至约8.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819041887c06485&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819041887c06485&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422166645","title":"百济神州发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2422166645","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422166645?lang=zh_cn&edition=full","pubTime":"2024-03-28 18:40","pubTimestamp":1711622446,"startTime":"0","endTime":"0","summary":"百济神州发布截至2023年12月31日止年度全年业绩,该集团期内取得收入合计24.59亿美元,同比增加73.65%;毛利20.79亿美元,同比增加84.06%;研发费用17.79亿美元,同比增加8.42%。公告称,随着百悦泽在全球特别是在美国和欧洲市场上市的持续成功,集团巩固了在血液肿瘤领域的领导地位。截至2023年12月31日止年度,百悦泽在中国的销售额总计1.938亿美元,同比增长28.9%,得益于所有获批适应症的销售增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281855328b6d7bf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281855328b6d7bf5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422950333","title":"百济神州诉外企侵犯专利 国内药企要学新的一课","url":"https://stock-news.laohu8.com/highlight/detail?id=2422950333","media":"经济观察网","top":-1,"share":"https://www.laohu8.com/m/news/2422950333?lang=zh_cn&edition=full","pubTime":"2024-03-27 17:20","pubTimestamp":1711531209,"startTime":"0","endTime":"0","summary":"3月下旬,接近百济神州专利诉讼事件的人士告诉经济观察网。去年6月,美国药企艾伯维旗下公司Pharmacyclics指控泽布替尼侵犯其伊布替尼专利,并已在美国地方法院提起诉讼。作为拥有国内第一个“十亿美元分子”的药企,百济神州无论是发起专利诉讼,还是应诉专利侵权指控,都是成长路上必须面对的功课。百济神州认为,山德士和MSN提交ANDA侵犯了橙皮书专利,并寻求永久禁令,以阻止两家公司商业化泽布替尼的仿制药。百济神州在公告中称。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032717252187bbbc58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032717252187bbbc58&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422955832","title":"百济神州-U03月27日遭主力抛售447万元 环比增加964.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422955832","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422955832?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:20","pubTimestamp":1711524000,"startTime":"0","endTime":"0","summary":"03月27日, 百济神州-U股价跌1.36%,报收130.24元,成交金额1.41亿元,换手率0.93%,振幅2.33%,量比0.83。百济神州-U今日主力资金净流出447万元,连续5日净流出,上一交易日主力净流出42万元,今日环比增加964.29%。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为66.67%,平均跌幅为2.51%。该股近5个交易日下跌7.55%,主力资金累计净流出5451万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出1.32亿元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271545418b68c813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271545418b68c813&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422010356","title":"百济神州3月26日获南向资金加仓54.59万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422010356","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422010356?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:31","pubTimestamp":1711503071,"startTime":"0","endTime":"0","summary":"3月26日, 南向资金增持百济神州54.59万股。截止当日收盘,港股通共持有百济神州5143.23万股,占流通股3.77%。百济神州近5个交易日下跌8.01%,港股通累计增持102.19万股;近20个交易日下跌5.50%,港股通累计增持225.55万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270943478b678e28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270943478b678e28&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422570699","title":"百济神州(苏州)生物科技有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2422570699","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422570699?lang=zh_cn&edition=full","pubTime":"2024-03-26 06:41","pubTimestamp":1711406494,"startTime":"0","endTime":"0","summary":"金融界3月26日消息,据CDE官网沟通交流公示,于3月26日收到百济神州(苏州)生物科技有限公司申请的“III类会议”,当前状态“处理中”。根据《药物研发与技术审评沟通交流管理办法》(2020年第48号通告),沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议,就关键阶段重大问题进行沟通交流,Ⅲ类会议一般安排在申请后75日内召开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260641378b62b078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260641378b62b078&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422687793","title":"医药行业周报:安进/百济神州双抗疗法在中国启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422687793","media":"太平洋证券股份...","top":-1,"share":"https://www.laohu8.com/m/news/2422687793?lang=zh_cn&edition=full","pubTime":"2024-03-26 00:00","pubTimestamp":1711382400,"startTime":"0","endTime":"0","summary":"行业要闻:近日,中国药物临床试验登记与信息公示平台官网显示,安进和百济神州共同启动了一项国际多中心(含中国)3 期临床研究,以评价局限期小细胞肺癌放化疗后进行Tarlatamab 治疗的有效性和安全性,该药为一款靶向DLL3 和CD3 的双特异性T 细胞衔接蛋白,百济神州拥有该药的中国商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422611475","title":"百济神州-U03月25日主力资金流出1502万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422611475","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422611475?lang=zh_cn&edition=full","pubTime":"2024-03-25 15:18","pubTimestamp":1711351099,"startTime":"0","endTime":"0","summary":"03月25日, 百济神州-U股价跌1.25%,报收131.67元,成交金额1.66亿元,换手率1.09%,振幅3.30%,量比0.90。百济神州-U今日主力资金净流出1502万元,连续3日净流出,上一交易日主力净流出2131万元,今日环比减少29.52%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为53.33%,平均跌幅为1.14%。该股近5个交易日下跌5.74%,主力资金累计净流出3676万元;近20日主力资金累计净流出8437万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251529368b60081d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251529368b60081d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422173580","title":"创新药融资承压,百济神州还能跨过盈亏平衡线吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2422173580","media":"松果财经","top":-1,"share":"https://www.laohu8.com/m/news/2422173580?lang=zh_cn&edition=full","pubTime":"2024-03-25 09:34","pubTimestamp":1711330482,"startTime":"0","endTime":"0","summary":"以百济神州为例。2023年,百济神州营收同比增速达到了惊人的74%。显然,资本希望创新药企能更好地平衡规模和盈利之间的关系。但由于创新药是技术密集型、人才密集型的行业,百济神州2023年包括研发费用、销售及管理费用、无形资产摊销三项在内的经营费用仍然同比增长12.6%。近日,百济神州宣布百泽安将于2024年下半年在美国上市,这是第二款在美成功获批的国产PD-1,有较大可能成为百济神州的“第二支柱”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403250935028b5f001f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403250935028b5f001f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421811806","title":"百济神州盘中异动 早盘急速跳水5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421811806","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421811806?lang=zh_cn&edition=full","pubTime":"2024-03-22 21:37","pubTimestamp":1711114678,"startTime":"0","endTime":"0","summary":"北京时间2024年03月22日21时37分,百济神州股票出现波动,股价快速跳水5.27%。百济神州股票所在的生物技术行业中,整体涨幅为0.44%。作为反击,百济神州提起专利侵权诉讼。无论是艾伯维起诉百济神州,还是百济神州对仿制药企发起反击,这些专利纠纷背后隐藏的,实则是商业利益之争。而百济神州的这场出海专利攻防战,也为市场敲响了警钟。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322213759861e06fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322213759861e06fc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421183140","title":"百济神州(06160)股价下跌8.095%,现价港币$93.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2421183140","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2421183140?lang=zh_cn&edition=full","pubTime":"2024-03-22 11:56","pubTimestamp":1711079760,"startTime":"0","endTime":"0","summary":"[下跌股]百济神州(06160) 股价在上午11:56比前收市价下跌8.095%,现股价为港币$93.1。至目前为止,今日最高价为$99.25,而最低价为$93.1。总成交量为74.3万股,总成交金额为港币$7.14千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403224826/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2421007729","title":"百济神州获融资买入0.13亿元,近三日累计买入0.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421007729","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421007729?lang=zh_cn&edition=full","pubTime":"2024-03-22 08:21","pubTimestamp":1711066908,"startTime":"0","endTime":"0","summary":"3月21日,沪深两融数据显示,百济神州获融资买入额0.13亿元,居两市第728位,当日融资偿还额0.11亿元,净买入188.21万元。最近三个交易日,19日-21日,百济神州分别获融资买入0.07亿元、0.09亿元、0.13亿元。融券方面,当日融券卖出2.82万股,净卖出2.29万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220821548b52dbd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220821548b52dbd8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421092266","title":"百济神州:公司独立非执行董事Olivier Brandicourt博士获委任为董事会商业及医学事务咨询委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2421092266","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2421092266?lang=zh_cn&edition=full","pubTime":"2024-03-21 17:23","pubTimestamp":1711012980,"startTime":"0","endTime":"0","summary":"百济神州(SH 688235,收盘价:138元)3月21日晚间发布公告称,经百济神州有限公司董事会审议通过,自2024年3月19日起,公司独立非执行董事Olivier Brandicourt博士获委任为董事会商业及医学事务咨询委员会成员。2022年1至12月份,百济神州的营业收入构成为:医药制造业占比100.0%。截至发稿,百济神州市值为1873亿元。(文章来源:每日经济新闻)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032117255287a13b39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032117255287a13b39&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420392739","title":"百济神州获北向资金卖出2214.5万元,累计持股475.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420392739","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420392739?lang=zh_cn&edition=full","pubTime":"2024-03-20 08:31","pubTimestamp":1710894709,"startTime":"0","endTime":"0","summary":"3月20日,巨灵财经数据显示,北向资金19日减持百济神州预估2214.5万元,累计持股475.9万股,总计持有市值6.65亿元,占流通股比例4.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320083150879a4217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320083150879a4217&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420738673","title":"人工智能+”行动出台,哪些板块有望受益?","url":"https://stock-news.laohu8.com/highlight/detail?id=2420738673","media":"银华基金","top":-1,"share":"https://www.laohu8.com/m/news/2420738673?lang=zh_cn&edition=full","pubTime":"2024-03-20 07:30","pubTimestamp":1710891050,"startTime":"0","endTime":"0","summary":"“人工智能+”行动有望拉动算力全产业链发展,国产化进程有望加速。整体我国AI全产业链供需两端具有较为良好的基础,“人工智能+”行动顶层设计的出台,有望进一步推动产业链相关科技创新企业的成长斜率。在“人工智能+”行动加持科技创新赛道、市场开启技术性反弹的大背景下,高弹性、高锐度的科创100指数有望成为进攻性看多市场中“锋利的矛”!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403200715407a4dbe50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403200715407a4dbe50&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420419453","title":"百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2420419453","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420419453?lang=zh_cn&edition=full","pubTime":"2024-03-18 13:34","pubTimestamp":1710740040,"startTime":"0","endTime":"0","summary":"[大手成交]百济神州(06160)在下午01:34出现大手卖出,成交量为10万,成交价为港币$101.95,涉资1.02千万。至目前为止,股价跌1.731%,今日最高价为$104.0,而最低价为$99.85,总成交量为115.992万股,总成交金额港币$1.174亿。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2403182317/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2420141634","title":"美银证券升百济神州目标价至108.27港元 评级中性","url":"https://stock-news.laohu8.com/highlight/detail?id=2420141634","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2420141634?lang=zh_cn&edition=full","pubTime":"2024-03-18 13:16","pubTimestamp":1710738960,"startTime":"0","endTime":"0","summary":"3月18日讯,美银证券发表报告指,因应百济神州(06160.HK)的收入变化,将公司2024至2026年的每股盈利预测分别调整-3%/100%/4%。鉴于公司的药物管道开发进展顺利,该行将百济神州的目标价由103.5港元上调至108.27港元,并重申中性评级。该行亦指,因应美国食品药物管理局(FDA)批准使用百济神州开发的替雷利珠单抗,而且相关药物于1月份的样品销售表现强劲,该行将公司2024年至2026年的整体营业收入预测分别上调0.9%/1.2%/0.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031813171187916676&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031813171187916676&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420355499","title":"大行评级|里昂:上调百济神州目标价至138.5港元 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2420355499","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2420355499?lang=zh_cn&edition=full","pubTime":"2024-03-18 10:52","pubTimestamp":1710730352,"startTime":"0","endTime":"0","summary":"里昂发表研究报告指,百济神州的核心产品PD-1替雷利珠单抗新药上市申请近日获美国FDA批准,可用于治疗2L级食管鳞状细胞癌的成人患者,符合该行预期及公司指引。该行认为,虽然海外市场已相当发展成熟,但相信此次申请获批对公司而言是一个渐进的利好消息,将2024至2026年营收预测上调1.3%、0.9%及0.9%,净亏损预期收窄2.8%、3.6%及10%,相应将H股目标价从136.7港元上调至138.5港元,重申“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181052378b4120fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181052378b4120fa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420460688","title":"百济神州3月15日获南向资金加仓79.97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420460688","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420460688?lang=zh_cn&edition=full","pubTime":"2024-03-18 09:31","pubTimestamp":1710725490,"startTime":"0","endTime":"0","summary":"3月15日, 南向资金增持百济神州79.97万股。截止当日收盘,港股通共持有百济神州4943.04万股,占流通股3.63%。百济神州近5个交易日上涨7.11%,港股通累计增持69.22万股;近20个交易日上涨14.92%,港股通累计减持14.64万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403180945288b40e15f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403180945288b40e15f&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-15","address":"MourantGovernanceServices(Cayman)Limited,94SolarisAvenue,CamanaBay,POBox1348,GrandCaymanKY1-1108,CaymanIslands","stockEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":0.0458},{"period":"3month","weight":-0.0595},{"period":"6month","weight":-0.0742},{"period":"1year","weight":-0.0086},{"period":"ytd","weight":-0.0595}],"companyName":"百济神州有限公司","boardCode":"AI0027","perCapita":"2823股","boardName":"医药制造业","registeredCapital":"13万元","compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.012},{"period":"6month","weight":-0.0321},{"period":"1year","weight":-0.0708},{"period":"ytd","weight":0.012}],"survey":" 百济神州有限公司是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物,主要产品百悦泽((BRUKINSA),BTK抑制剂)、百泽安(抗PD-1单抗)、帕米帕利。公司自主研发产品BRUKINSA(百悦泽)实现了中国原研新药出海的“零突破”,并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年,公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外,公司作为承担单位进行了5项国家级科研项目,并在核心期刊上发表了34篇学术论文。","serverTime":1711647434421,"listedPrice":192.6,"stockholders":"40746人(较上一季度减少6.73%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}